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Type 2 diabetes is characterized by excessive lipid storage in
skeletal muscle. Excessive intramyocellular lipid (IMCL) storage
exceeds intracellular needs and induces lipotoxic events, ulti-
mately contributing to the development of insulin resistance.
Lipid droplet (LD)–coating proteins may control proper lipid
storage in skeletal muscle. Perilipin 2 (PLIN2/adipose differenti-
ation–related protein [ADRP]) is one of the most abundantly
expressed LD-coating proteins in skeletal muscle. Here we exam-
ined the role of PLIN2 in myocellular lipid handling and insulin
sensitivity by investigating the effects of in vitro PLIN2 knock-
down and in vitro and in vivo overexpression. PLIN2 knockdown
decreased LD formation and triacylglycerol (TAG) storage, mar-
ginally increased fatty-acid (FA) oxidation, and increased incor-
poration of palmitate into diacylglycerols and phospholipids.
PLIN2 overexpression in vitro increased intramyocellular TAG
storage paralleled with improved insulin sensitivity. In vivo
muscle-specific PLIN2 overexpression resulted in increased
LD accumulation and blunted the high-fat diet–induced in-
crease in protein content of the subunits of the oxidative phos-
phorylation (OXPHOS) chain. Diacylglycerol levels were unchanged,
whereas ceramide levels were increased. Despite the increased
IMCL accumulation, PLIN2 overexpression improved skeletal mus-
cle insulin sensitivity. We conclude that PLIN2 is essential for lipid
storage in skeletal muscle by enhancing the partitioning of excess
FAs toward TAG storage in LDs, thereby blunting lipotoxicity-asso-
ciated insulin resistance. Diabetes 61:2679–2690, 2012
L
ipid droplets (LDs) serve an essential function in
eukaryotic cells. Accordingly, intracellular lipid
levels need to be tightly controlled. Indeed, inappro-
priate intracellular lipid storage leads to impaired
cellular function. In obesity, lipids will overflow into the
circulation as a result of lack of storage capacity in adipose
tissue, and, as a consequence, lipids may accumulate ectop-
ically in tissues, including skeletal muscle (intramyocellular
lipids [IMCLs]). This ectopic fat storage exceeds in-
tracellular demand and may result in lipotoxic events,
including the development of insulin resistance (1,2). Para-
doxically, IMCL is increased in both endurance-trained
athletes and type 2 diabetic patients (3,4), indicating that
ectopic lipid accumulation per se does not induce insulin
resistance.
Thus far, explanations for this athlete’s paradox have
focused on lipid turnover, oxidative capacity, and levels of
lipid intermediates (5–8). Interestingly, one exercise ses-
sion was shown to prevent lipid-induced insulin resistance
by partitioning more fatty acids (FAs) toward triacylglycerol
(TAG) synthesis in skeletal muscle (9). Therefore, increasing
the depot for TAG storage might improve insulin sensitivity.
Intracellular TAG is stored in LDs, which are increasingly
recognized as dynamic organelles. They are composed of a
neutral lipid core containing TAG, diacylglycerol (DAG),
cholesterolesters, retinol esters, and free cholesterol (10)
surrounded by a phospholipid monolayer (11) and a pro-
tein coat, composed of a variety of LD-coating proteins (12).
Accumulating evidence suggests that LD-coating proteins
mediate LD dynamics, including LD synthesis, growth and
fusion, intracellular transport, organelle interactions, and
breakdown and lipolysis (13,14).
The best-characterized family of LD-coating proteins is
the perilipin (PLIN) protein family, including PLIN1, PLIN2
(adipophilipin and adipose differentiation–related protein
[ADRP]), PLIN3 (tail-interacting protein, 47 kDa [TIP47]),
PLIN4 (adipocyte protein S3-12), and PLIN5 (OXPAT, lipid
droplet storage protein 5 [LSDP5]). Whereas PLIN1 expres-
sion is restricted to adipose tissue, where it plays a crucial
role in the control of storage and degradation of LDs (15,16),
PLIN2 is expressed in several tissues, including liver, small
intestine, and skeletal muscle (17,18). PLIN2 in skeletal
muscle was previously shown to colocalize with IMCL (19).
Interestingly, skeletal muscle Plin2 gene expression was
shown to be lower in patients with type 2 diabetes versus
obese control subjects (20). Furthermore, weight loss as well
as metformin treatment, both resulting in lower IMCL levels
(21,22), were demonstrated to increase skeletal muscle
PLIN2 levels in parallel with improved insulin sensitivity (23).
PLIN2 may be involved in the protection against lipotoxicity
by facilitating efficient IMCL storage in the form of TAG.
However, loss- and gain-of-function studies to characterize
PLIN2 function in skeletal muscle, required to obtain more
functional insight into the role of PLIN2 in muscle, have not
been performed to date. Here, we aimed to examine the role
of PLIN2 in myocellular fat accumulation, lipotoxicity, and
insulin sensitivity.
RESEARCH DESIGN AND METHODS
Cell culture experiments. C2C12 cells (LGC, Teddington, U.K.) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
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Breda, the Netherlands) containing antibiotics supplemented with 10% FCS,
grown on extracellular matrix (ECM) gel–coated (Sigma-Aldrich, St. Louis,
MO) cell culture plates, and differentiated over the course of a week in DMEM
supplemented with 2% FCS (differentiation media). Cells were treated with
200–800 mmol/L FAs (6–24 h) (octanoic, oleic, or palmitic acid conjugated to
BSA; ratio BSA to FA, 1:2.5) or solely BSA as a control. For inhibitory RNA
(RNAi) experiments, cells were transfected with 10 nmol/L Stealth RNAi oli-
gos using Lipofectamine RNAiMAX (Invitrogen) as transfection reagent. PLIN2
overexpression was achieved by transfections with pENTR1A-pUC Plin2
construct with Lipofectamine-2000 (Invitrogen).
Lipid metabolism. In vitro 14C-palmitate metabolism was measured as pre-
viously described (24). Intracellular triglyceride levels were measured using
the method of Schwartz and Wolins (25).
Glucose uptake assay.Glucose uptake was measured as previously described
(26).
Animal studies. C57Bl6 mice were fed a low-fat (10% energy from fat) or
a high-fat diet (HFD; 45% energy from fat) (Research Diet Services, Wijk bij
Duurstede, the Netherlands) for 8 weeks. Tibialis anterior (TA) was dissected.
Seven-week-old male Wistar rats were purchased from Charles River (Wilmington,
MA). Rats were fed either a chow diet (n = 4) (SSNIFF; Bio Services, Uden, the
Netherlands) or an HFD (n = 12) (45% energy from fat, D01060502; Research
Diets, New Brunswick, NJ). The Institutional Animal Care and Use Committee
of Maastricht University approved the experiments. The total intervention
lasted 3 weeks. One week after the start of the diets, rats were cannulated,
followed by gene electroporation and the hyperinsulinemic euglycemic clamp,
with 1-week recovery periods in-between.
Electroporation. Overexpression of mouse PLIN2 in the left TA muscle of the
rat was accomplished by an in vivo DNA electroporation technique under iso-
flurane anesthesia. Left TA muscles were transcutaneously injected with 75 mg
pENTR1A-pUC Plin2 construct, and right TA muscles were injected with empty
vector as a control. Within 15 s after the last injection, one high-voltage pulse of
800 V/cm and four low-voltage pulses of 80 V/cm at 1 Hz were generated by an
ECM 830 electroporator (BTX, San Diego, CA), as described previously (27).
Hyperinsulinemic euglycemic clamp. Clamps were performed as previously
described (28). In brief, after a 6-h fast, a continuous infusion of insulin was
administered at a rate of 13 mU/kg/min for 120 min. The glucose infusion rate was
adjusted to maintain blood glucose concentration within the range of 4.5–5.5
mmol/L. Rats were conscious during the full procedure. At 45 min before com-
pletion of the clamp, a bolus of 140 mCi/kg of 2-(3H(N))-deoxy-D-glucose was
administered.
Lipid species. Skeletal muscle DAG, TAG, and ceramide levels were measured
as previously described (28).
Western blots. Western blotting studies were performed using antibodies
directed against PLIN2 (Progen, Heidelberg, Germany), PLIN3 (Santa Cruz,
Heidelberg, Germany), PLIN5 (Progen), Akt phosphorylation (pAkt) and Akt,
adipose triglyceride lipase (ATGL) (Cell Signaling Technology, Leiden, the
Netherlands), comparative gene identification 58 (CGI-58) (Novus Biologicals,
Littleton, CO), peroxisome proliferator–activated receptor g coactivator 1-a
(PGC1a) (Calbiochem, Amsterdam, the Netherlands), uncoupling protein 3
(UCP3) (provided by L.J. Slieker, Eli Lilly), and OXPHOS (Mitosciences,
Eugene, OR). Protein expression values were standardized against actin pro-
tein expression (Sigma-Aldrich, St. Louis, MO). Secondary antibodies con-
tained an infrared dye. Protein quantification was performed by scanning on
an Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE).
Statistical analysis. Differences between groups were evaluated with uni-
variate ANOVA followed by Tukey honestly significant difference post hoc tests
(cell studies) and unpaired (cell studies) or paired Student t tests (animal
experiments). P , 0.05 was considered statistically significant.
RESULTS
PLIN2 protein expression is induced upon lipid
loading. We first examined if TAG accumulation in
myotubes is indeed associated with altered expression of
PLIN2. To this end, C2C12 mouse myotubes were incubated
with different types of FAs (200 mmol/L) (Fig. 1A). Octanoate,
a short-chain FA that is preferentially oxidized, did not
increase TAG levels, whereas incubation with either oleate
or palmitate led to marked accumulation of myocellular TAG
as well as an increase in PLIN2 protein expression. The
induction of PLIN2 protein levels was dependent on FA
concentration, but reached the maximal induction at an FA
concentration of 200 mmol/L (Supplementary Fig. 1A), and
on FA incubation time, when the FA concentration was held
constant at 200 mmol/L (Supplementary Fig. 1B). Next we
determined the in vivo effects of lipid overload on PLIN2
protein content. We found that both an 8-week HFD (Fig. 1B)
and 6 or 24 h of fasting (Supplementary Fig. 1C) significantly
increased PLIN2 protein levels in mouse skeletal muscle.
PLIN2 is essential for intracellular LD storage. To
obtain further insight into the importance of PLIN2 for ef-
ficient TAG storage, we knocked down PLIN2 in myotubes
using small interfering RNA (siRNA). Compared with PLIN2
levels in cells transfected with a scrambled control oligo,
Plin2 mRNA levels were reduced by 90% (Supplementary
Fig. 2A) and protein levels decreased with 85% on average
(Fig. 1C). The knockdown of PLIN2 prevented FA-induced
TAG accumulation and LD formation even upon oleate or
palmitate incubation, demonstrating that PLIN2 is essen-
tial for TAG storage in LDs (Fig. 1D–F). Protein expression
of the LD-coating protein PLIN3 was not affected by PLIN2
knockdown, excluding a compensatory increase of this
protein (Supplementary Fig. 2B). Please note that the LD-
coating proteins PLIN1, PLIN4, and PLIN5 are not expressed
in C2C12 cells. Electron microscopic imaging confirmed
that oleate and palmitate led to massive lipid accumulation
in control cells, whereas this lipid accumulation was large-
ly absent after FA loading in the PLIN2 knockdown cells
(Fig. 1D and E). The few LDs that were present in PLIN2
knockdown cells were markedly larger in size compared
with control cells.
Knockdown of PLIN2 increases the cellular oxidative
capacity. The lack of LD storage capacity in PLIN2 knock-
down cells may be compensated by enhanced fat oxidative
capacity or reduced FA uptake. To investigate these possi-
bilities, we used an unbiased approach by implementing
a whole-genome expression analysis in the PLIN2 knock-
down cells (Fig. 2 and Table 1). Specifically, overrepresen-
tation analysis of functional gene ontology classes showed
suppression of numerous pathways related to FA transport
and lipid storage (Fig. 2). Examples of genes that were
downregulated upon PLIN2 knockdown include Fads2 and
Agpat9 (Table 1). Furthermore, gene ontology classes cor-
responding to respiratory electron transport chain and glu-
cose/carbohydrate metabolism were increased upon PLIN2
knockdown (Fig. 2), indicating a compensatory increase in
expression of genes involved in mitochondrial function
(average PLIN2 knockdown effect across treatment condi-
tions: Pgc1a fold change (FC) = 3.2, Mterf FC = 2.2, Mrps33
FC = 1.5, Mfn1 FC = 1.3, and Mtrf1l FC = 1.8) (Table 1).
Consistent with the gene expression levels, knockdown
of PLIN2 increased protein expression of OXPHOS com-
plexes (total OXPHOS univariate ANOVA PLIN2 knockdown
effect P , 0.05; complex I, P = 0.095; II, P = 0.052; III, P ,
0.05; and V, P , 0.01) (Fig. 3A and Supplementary Fig. 3).
Therefore, we next investigated whether PLIN2 knockdown
resulted in a compensatory increased capacity to oxidize fat
in order to deal with the lower capacity for lipid storage by
measuring 14C-palmitate oxidation. Knockdown of PLIN2
tended to increase total 14C-palmitate oxidation (P = 0.055)
(Fig. 3B). However, complete 14C-palmitate oxidation to CO2
was not affected (Fig. 3C). Instead, the tendency toward in-
creased 14C-palmitate oxidation can probably be ascribed to
an increase in incomplete oxidation (acid-soluble metabolites
[ASMs]; P = 0.108) (Fig. 3D). Thus, PLIN2 knockdown effects
on palmitate oxidation were modest, indicating that the in-
creased mitochondrial density only partly compensated for
the reduction in TAG storage capacity.
Knockdown of PLIN2 increases palmitate incorporation
into DAG and phospholipids. In the PLIN2 knockdown
situation, the lack of the capacity to store FAs as TAG in LDs
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resulted in a trend toward increased total FA oxidation, with
the majority of 14C-palmitate being incompletely oxidized
and accounted for in 14C-ASMs. Thus, another possibility to
deal with FAs in the absence of cellular TAG storage capacity
would be to store FAs in lipid species other than TAG.
Therefore, 14C-palmitate incorporation into total neutral lipids,
TAG, DAG, and phospholipids was determined. Compared
with the scrambled control, a 3-h 14C-palmitate incuba-
tion of PLIN2 knockdown cells resulted in a lower in-
corporation of palmitate in the total neutral lipid pool
(P , 0.01) (Fig. 3E). Besides decreased total intracellular
lipid storage, FA incorporation into neutral lipids shifted
from TAG toward DAG and phospholipids. 14C-palmitate
incorporation into phospholipids and DAG was increased
FIG. 1. PLIN2 knockdown lowers intracellular neutral lipid accumulation. A: C2C12 myotubes were incubated overnight with 80 mmol/L BSA
complexed to 200 mmol/L oleate (OA), palmitate (PA), octanoate (OctA), or solely BSA as a control. PLIN2 and TAG levels are expressed as fold
change relative to the control treatment. *P < 0.05 compared with the control treatment. B: PLIN2 protein expression in TA muscle of C57Bl6
mice fed an HFD or normal chow diet for 8 weeks. C and D: C2C12 myotubes were transfected with PLIN2 siRNA (P2) or a scrambled control (S)
and incubated overnight with 200 mmol/L BSA-coupled oleate, palmitate, or solely 80 mmol/L BSA. Subsequently, cells were harvested to
measure PLIN2 protein expression and TAG levels. #P < 0.05 vs. control (FA effect) and *P < 0.05 vs. scrambled control with the corresponding
FA treatment. Data are expressed as mean 6 SEM. n = 3–4. D and E: Electron microscopy pictures. D scale bars represent 2 microns. E: The
oleate-treatment condition (increased LD size upon PLIN2 knockdown). Scale bars represent 0.5 micron.
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in the PLIN2 knockdown cells compared with the
scrambled control cells (P , 0.01 and P , 0.05, respec-
tively), balancing the lower incorporation into TAG (P ,
0.01) (Fig. 3F–H). PLIN2 knockdown did not compromise
insulin signaling (P = 0.0528 for basal pAkt, P = 0.82 for
insulin stimulated pAkt, and P = 0.094 for deoxyglucose
uptake) (Fig. 3I and J).
In summary, PLIN2 is essential for LD formation and
stability and intracellular TAG storage. PLIN2 knockdown
increases FA oxidation only marginally.
PLIN2 overexpression protects against palmitate-
induced impairments in insulin-stimulated glucose
uptake. Lipid intermediate accumulation other than TAG
storage is considered to negatively affect insulin signaling
(30), whereas efficient TAG storage is considered harm-
less (28,31). Results from the PLIN2 knockdown studies
illustrate that PLIN2 is necessary for efficient storage of
FAs into inert TAG. Therefore, we next investigated
whether overexpression of PLIN2 could facilitate effi-
cient muscle TAG storage, and thereby prevent fat-
induced impairments in insulin signaling. Hence, we
overexpressed PLIN2 in vitro in order to investigate its
potential beneficial effects on IMCL handling. PLIN2
overexpression resulted in a twofold increase in PLIN2
expression (Fig. 4A), a sixfold increased intracellular
TAG storage (P = 0.04) (Fig. 4B), and increased 14C-
palmitate incorporation into total neutral lipids (P =
0.013), DAG, and TAG (P = 0.003 and P = 0.042,
respectively) while decreasing its incorporation into
phospholipids (P = 0.006) (Fig. 4C–F). We next tested if
PLIN2-facilitated intramyocellular TAG storage could pre-
vent palmitate-induced disruptions in insulin signaling.
To this end, PLIN2- and empty vector–transfected C2C12
myotubes were incubated overnight with 400 mmol/L
palmitate, known to impair insulin signaling (32). In
line with the hypothesis, PLIN2 overexpression rescued
palmitate-mediated impairments in insulin-stimulated glu-
cose uptake (P , 0.05) (Fig. 4G).
In vivo, unilateral overexpression of PLIN2. To in-
vestigate if PLIN2 overexpression also has beneficial
effects on insulin sensitivity in vivo, we overexpressed
PLIN2 unilaterally in muscle of rats fed chow or HFD.
We used an in vivo gene electroporation method to
achieve ectopic PLIN2 expression in rat TA muscle in one
leg, using the contralateral leg of the same animal as
control. Marked overexpression of PLIN2 in rat TA muscle
was obtained, as demonstrated by Western blotting
(2.5-fold on average in whole-muscle lysates) (Fig. 5A),
as well as immunofluorescence showing numerous LDs
coated by PLIN2 (Fig. 5B). LDs in PLIN2-overexpressing
muscle were larger and more numerous (Fig. 5B and C),
indicating increased IMCL levels upon PLIN2 over-
expression.
An unbiased whole-genome expression analysis re-
vealed that genes related to lipid metabolism and mito-
chondrial FA oxidation were differentially regulated in
PLIN2-electroporated versus control muscle in rats on the
HFD (Table 2 and Supplementary Fig. 4). More specifi-
cally, examples of genes that were downregulated upon
PLIN2 overexpression included Pgc1a (FC = 21.92), Cpt2
(FC = 21.74), and the mitofusins (Mfn1 FC = 21.53; Mfn2
FC = 21.53) (Table 2). This group of downregulated genes
was overrepresented in gene sets linked with oxidative
phosphorylation, FA oxidation, and mitochondrial func-
tion (Supplementary Fig. 4) and included peroxisome
proliferator–activated receptor a (PPARa) target genes
(Supplementary Fig. 5). Upregulated genes included
SCD1 (FC = 1.62) and PPARg (FC = 1.57) and were asso-
ciated with gene sets related to lipid storage and carbohy-
drate metabolism (Table 2). Thus, PLIN2 overexpression
was associated with a metabolic profile consistent with
a shift from FA oxidation toward lipid storage.
FIG. 2. Gene expression profiles of PLIN2 knockdown in C2C12 myotubes. Selected pathways identified by gene score resampling in ErmineJ. Only
pathways that were significantly up- or downregulated (P < 0.05) are shown. The enrichment score reflects the degree to which a gene set is
overrepresented at the top (upregulated, positive score) or bottom (downregulated, negative score) of the ranked gene list and is corrected for
gene set size. Black bars, control condition; gray bars, oleate; white bars, palmitate treatment. Microarray data have been submitted to Gene
Expression Omnibus (GSE38590).
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PLIN2 overexpression induces changes in the ex-
pression of proteins involved in lipid metabolism.
Western blottings were performed to extend the PLIN2
overexpression–mediated changes in gene expression to
proteins involved in mitochondrial function (OXPHOS,
PGC1a, and UCP3) and lipolysis (ATGL, CGI-58, and PLIN5).
In the chow-fed group of animals, no significant changes
in protein expression were observed upon PLIN2 over-
expression. However, in rats fed the HFD for 4 weeks,
protein levels of OXPHOS complexes I, III, and V tended
to be decreased by PLIN2 overexpression (P = 0.075 for
complex II) (Supplementary Fig. 6A), suggesting that the
HFD-induced upregulation of OXPHOS protein expres-
sion was blunted by PLIN2 overexpression. These results
corresponded with the observed lower gene expression
levels of genes related to mitochondrial function and FA
oxidation (Table 2 and Supplementary Fig. 4). PGC1a
protein expression as well as PLIN5, another LD-coating
protein that is supposed to be involved in oxidative processes
(33), tended to be decreased upon PLIN2 overexpression
TABLE 1
Expression patterns of a selection of genes in the six treatment conditions, derived from pools of four samples per treatment condition
Negative control PLIN2 knockdown
Gene GeneID Gene name Control Oleate Palmitate Control Oleate Palmitate
Adfp 11520 Adipose differentiation–related protein 1 1.68 1.79 0.21 0.32 0.30
M6prbp1 66905 Mannose-6-phosphate receptor
binding protein 1 (TIP47)
1 1.06 0.97 1.07 0.98 1.07
Dgke 56077 Diacylglycerol kinase, ´ 1 1.23 0.66 1.81 2.02 1.97
Fads2 56473 Fatty acid desaturase 2 1 0.51 1.30 0.53 0.33 0.73
Pltp 18830 Phospholipid transfer protein 1 1.31 0.83 0.41 0.44 0.37
Smpdl3b 100340 Sphingomyelin phosphodiesterase,
acid-like 3B
1 1.01 0.88 0.42 0.41 0.55
Elovl4 83603 Elongation of very long-chain fatty
acids-like 4
1 0.99 0.85 0.65 0.70 0.53
Agpat4 68262 1-Acylglycerol-3-phosphate
O-acyltransferase 4
1 1.01 0.91 0.51 0.57 0.57
Agpat9 231510 1-Acylglycerol-3-phosphate
O-acyltransferase 9
1 1.33 1.42 0.50 0.61 0.59
Dgat2 67800 Diacylglycerol O-acyltransferase 2 1 0.84 0.75 0.60 0.53 0.58
Dhrs3 20148 Dehydrogenase/reductase (SDR family)
member 3
1 1.30 1.95 0.58 0.74 0.66
Erlin2 244373 Endoplasmic reticulum lipid raft–associated 2 1 1.12 1.07 1.70 1.53 1.70
Erlin1 226144 Endoplasmic reticulum lipid raft–associated 1 1 1.25 1.13 1.47 1.68 1.70
Ppara 19013 PPARa 1 1.28 1.00 1.75 1.59 1.50
Ppargc1a 19017 PGC1a 1 1.12 0.81 3.46 2.96 2.95
Mterf 545725 Mitochondrial transcription termination factor 1 2.17 1.09 4.02 1.85 2.02
Mrps33 14548 Mitochondrial ribosomal protein S33 1 1.33 1.38 2.00 2.18 1.30
Car3 12350 Carbonic anhydrase 3 1 1.25 0.82 12.38 12.68 11.46
Mfn1 67414 Mitofusin 1 1 1.01 0.95 1.29 1.37 1.31
Cpt1b 12895 Carnitine palmitoyltransferase 1b, muscle 1 2.36 1.40 0.69 1.19 0.89
Mtrf1 L 108853 Mitochondrial translational release factor 1-like 1 1.40 1.26 2.32 2.07 1.93
Atp5g1 11951 ATP synthase, H+ transporting, mitochondrial F0
complex, subunit c isoform 1
1 1.92 0.91 1.04 2.73 0.97
Pdk2 18604 Pyruvate dehydrogenase kinase, isoenzyme 2 1 0.98 0.84 1.74 1.94 1.68
Mlycd 56690 Malonyl-CoA decarboxylase 1 1.82 1.01 1.19 1.67 1.57
Atp13a5 268878 ATPase type 13A5 1 1.05 0.72 2.85 2.68 2.31
Gk5 235533 Glycerol kinase 5 1 1.00 0.79 1.35 1.55 1.60
Lctl 235435 Lactase-like 1 0.64 0.95 0.31 0.25 0.29
Rrad 56437 Ras-related associated with diabetes 1 0.76 1.30 0.29 0.26 0.45
Rassf2 215653 Ras association (RalGDS/AF-6) domain
familymember 2
1 1.09 0.78 0.23 0.20 0.27
Fgf21 56636 Fibroblast growth factor 21 1 0.77 0.84 0.21 0.23 0.20
Pld1 18805 Phospholipase D1 1 1.18 0.83 1.62 1.56 1.63
Atf3 11910 Activating transcription factor 3 1 1.05 1.97 0.40 0.43 0.42
Igfbp3 16009 Insulin-like growth factor binding protein 3 1 0.70 0.78 4.71 4.22 4.00
Mapk1 26413 Mitogen-activated protein kinase 1 1 1.08 0.92 1.31 1.28 1.35
Gga2 74105 Golgi-associated, g adaptin ear containing, ARF
binding protein 2
1 0.92 0.82 1.81 1.89 1.95
Gpr56 14766 G protein-coupled receptor 56 1 0.59 0.88 0.09 0.08 0.09
Purb 19291 Purine-rich element-binding protein B 1 1.01 1.16 0.46 0.47 0.51
Tnfrsf12a 27279 Tumor necrosis factor receptor superfamily,
member 12a
1 0.84 1.11 0.59 0.64 0.55
Expression levels in scrambled control cells without FA treatment were set at 1, and expression levels in other groups were related to
this reference condition. Microarray data have been submitted to Gene Expression Omnibus (GSE38590). Quantitative PCR was
performed for a selection of genes to validate the microarray data (Supplementary Fig. 3).
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(P = 0.062 and P = 0.078, respectively) (Supplementary
Fig. 6B and C). Protein expression of ATGL, CGI-58, and
UCP3 was not significantly changed (Supplementary
Fig. 6D–F).
PLIN2 overexpression augments myocellular fat
storage while blunting HFD-induced insulin resistance.
We next investigated if the enhanced TAG storage capacity
was associated with a reduction in the lipotoxic FA
intermediates DAG and ceramides. Interestingly, despite
increased IMCL accumulation, PLIN2 overexpression did
not increase DAG levels (Fig. 6A), nor was the FA compo-
sition (saturation and FA chain length) of the DAG fraction
affected by PLIN2 overexpression (Supplementary Fig. 7).
Thus, increased total IMCL levels in PLIN2-overexpressing
muscle were not paralleled by increased DAG levels, in-
dicating that FAs were stored as TAG. Intriguingly, cer-
amide levels were increased by 23% (Fig. 6B) upon PLIN2
overexpression.
PLIN2 overexpression thus increased IMCL levels con-
current with an altered gene expression profile favoring
FIG. 3. Altered lipid metabolism and oxidative capacity in PLIN2 knockdown cells. A: Protein expression of the OXPHOS complexes I, II, III, and V
in cell cultures transfected with either PLIN2 siRNA (P2) or scrambled control siRNA (S), expressed as arbitrary units (AU). n = 4 for each
treatment condition. OA, oleate; PA, palmitate. Analysis of 3-h
14





C ASMs) (B), complete oxidation to CO2 (C), and incomplete oxidation to ASMs (D). n = 6 per treatment condition.
14
C-palmitate incorporation into total neutral lipids (E), TAG (F), phospholipids (G), and DAG (H). Values were normalized to protein levels.
Incorporation into TAG, DAG, and phospholipids is expressed relative to the control condition. I: Insulin-stimulated deoxyglucose uptake.
J: Insulin-stimulated pAkt phosphorylation. *P < 0.05. Error bars represent SEM.
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efficient fat storage rather than oxidation. Therefore, we
investigated whether these consequences of PLIN2 over-
expression would affect insulin sensitivity. To this end,
a hyperinsulinemic euglycemic clamp was implemented.
As anticipated, rats on the HFD gained significantly more
weight compared with the rats on a control (chow) diet
(chow +1.91 6 0.41 vs. HFD +2.94 6 0.20 g/day, P = 0.01),
and an HFD feeding period of 3 weeks sufficed to impede
whole-body insulin sensitivity, as indicated by a lower
glucose infusion rate during the stable phase of the clamp
(chow 31.8 6 1.0 vs. HFD 26.6 6 1.6 mg/min/kg, P = 0.05).
PLIN2 overexpression effects on insulin sensitivity were
investigated in rats fed the HFD. During the stable phase
of the clamp, 3H-labeled deoxyglucose was administered
intravenously to investigate muscle-specific deoxyglucose
uptake, comparing the PLIN2-overexpressing TA muscle
with the control sham-electroporated muscle of the same
rat. Interestingly, despite the profoundly increased total
IMCL accumulation (Fig. 5B and C) and the increased
ceramide levels (Fig. 6B), insulin sensitivity was not impaired
in the PLIN2-overexpressing leg. Rather, deoxyglucose
uptake significantly increased by 11.1% in the PLIN2-
overexpressing leg compared with the control leg (P =
0.045) (Fig. 6C).
DISCUSSION
The protein coat of LDs is an important interface for the
regulation of intracellular lipid metabolism. PLIN2 is one
of the main LD-coating proteins in nonadipose tissues. In
the current study, we demonstrate that PLIN2 plays an
essential role in skeletal muscle IMCL storage. First, we
FIG. 4. PLIN2 overexpression protects against palmitate-induced insulin resistance in C2C12 myotubes. A: Western blot demonstrating
efficiency of PLIN2 overexpression. B: TAG levels. Incorporation into neutral lipids (C), TAG (D), DAG (E), and phospholipids (PL) (F).
Incorporation into TAG, DAG, and PL is expressed relative to the control condition. G: Insulin-stimulated deoxyglucose uptake. EV, empty
vector; PA, palmitate (400 mmol/L); PL, phospholipids; C, control; DPM, disintegrations per minute. *P < 0.05. Error bars represent SEM.
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FIG. 5. Gene electrotransfer–mediated overexpression of PLIN2 in rat TA muscle. A: Representative Western blot demonstrating over-
expression of PLIN2 in the left TA muscle. EV, empty vector. SR-actin, sarcomeric actin B: Lipid accumulation (red, Oil-Red-O) and PLIN2
expression (green) (overlap of PLIN2 and lipids appears yellow, but depends on the place of the cross-cut through the intracellular LDs) in
TA muscle sections of the right (control, empty vector) and left (PLIN2 vector) leg of rats fed an HFD. Cell membranes are stained in blue.
Representative pictures are shown. The image on the right bottom panel is a magnification of a selection of the picture above. C: Ultra-
structure (transmission electron microscopy [TEM]) of muscle samples from sham- and PLIN2-electroporated muscle. (A high-quality digital
representation of this figure is available in the online issue.)
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TABLE 2
Heat map
ID Fold change Gene Unigene Description
308100 2.63 Acat3 Rn.203063 Acetyl-CoA acetyltransferase 3
100359680 2.43 LOC100359680 Rn.81758 Lysophosphatidylcholine acyltransferase 2-like
313220 2.39 Acnat2 Rn.162815 Acyl-CoA amino acid N-acyltransferase 2
29347 2.23 Faah Rn.89119 Fatty acid amide hydrolase
499210 2.18 Acer3 Rn.19122 Alkaline ceramidase 3
500973 2.12 Slc37a2 Rn.224149 Solute carrier family 37
(glycerol-3-phosphate transporter), member 2
64035 2.09 Pygl Rn.21399 Phosphorylase, glycogen
360622 2.05 Igfbp4 Rn.160666 Insulin-like growth factor binding protein 4
361401 1.99 Pla2g15 Rn.93631 Phospholipase A2, group XV
83730 1.94 Vamp8 Rn.82672 Vesicle-associated membrane protein 8
296474 1.93 Pric285 Rn.47450 PPAR A interacting complex 285
24377 1.91 G6pd Rn.11040 Glucose-6-phosphate dehydrogenase
29411 1.9 Ppt1 Rn.1574 Palmitoyl-protein thioesterase 1
361527 1.9 Pld3 Rn.128036 Phospholipase D family, member 3
286896 1.83 Sgpl1 Rn.26953 Sphingosine-1-phosphate lyase 1
298199 1.76 Adfp Rn.101967 Adipose differentiation-related protein
296371 1.7 Pltp Rn.117434 Phospholipid transfer protein
288707 1.7 Gltp Rn.4111 Glycolipid transfer protein
29560 1.7 Hif1a Rn.10852 Hypoxia-inducible factor 1, a subunit
(basic helix-loop-helix transcription factor)
314649 1.69 S1pr4 Rn.225785 Sphingosine-1-phosphate receptor 4
294422 1.68 Smpdl3a Rn.8142 Sphingomyelin phosphodiesterase, acid-like 3A
361076 1.65 RGD1561955 Rn.200706 Similar to diacylglycerol kinase h
246074 1.64 Scd1 Rn.1023 Stearoyl-CoA desaturase 1
25096 1.63 Pld1 Rn.11130 Phospholipase D1
314360 1.6 Galc Rn.30608 Galactosylceramidase
54315 1.59 Ucp2 Rn.13333 Uncoupling protein 2
(mitochondrial, proton carrier)
24334 1.58 Eno2 Rn.10828 Enolase 2, g, neuronal
25664 1.57 Pparg Rn.23443 PPAR g
24654 1.53 Plcb1 Rn.45523 Phospholipase C, b 1 (phosphoinositide-specific)
25595 1.5 Map2 Rn.10484 Microtubule-associated protein 2
301265 23.19 Adhfe1 Rn.90768 Phospholipase A2, group VII
(platelet-activating factor acetylhydrolase, plasma)
291437 22.61 St3gal6 Rn.199051 Lipase, endothelial
81782 22.42 Cxcl14 Rn.59 Sterol O-acyltransferase 1
308100 22.38 Serhl2 Rn.203063 Acetyl-CoA acetyltransferase 3
117243 23.31 Acsl6 Rn.33697 Acyl-CoA synthetase long-chain family member 6
114508 23.17 Fbp2 Rn.15319 Fructose-1,6-bisphosphatase 2
25747 23.04 Ppara Rn.9753 PPARa
291135 22.71 Acot13 Rn.1730 Acyl-CoA thioesterase 13
79131 22.28 Fabp3 Rn.32566 Fatty acid binding protein 3, muscle and heart
311617 22.26 Fitm2 Rn.107822 Fat storage–inducing transmembrane protein 2
361637 22.24 Acsm5 Rn.35367 Acyl-CoA synthetase medium-chain family member 5
117035 22.05 Slc25a20 Rn.3289 Solute carrier family 25
(carnitine/acylcarnitine translocase), member 20
252898 21.95 Acox2 Rn.10622 Acyl-CoA oxidase 2, branched chain
171142 21.93 Ehhadh Rn.3671 Enoyl-CoA, hydratase/3-hydroxyacyl CoA
dehydrogenase
83516 21.92 Ppargc1a Rn.19172 PGC1a
64304 21.87 Acads Rn.1167 Acyl-CoA dehydrogenase, C-2 to C-3 short chain
29470 21.84 Mecr Rn.15375 Mitochondrial trans-2-enoyl-CoA reductase
25413 21.74 Cpt2 Rn.11389 Carnitine palmitoyltransferase 2
305166 21.72 Agpat9 Rn.214521 1-Acylglycerol-3-phosphate O-acyltransferase 9
25062 21.7 Gpd2 Rn.89705 Glycerol-3-phosphate dehydrogenase 2,
mitochondrial
305606 21.69 Mtif2 Rn.160632 Mitochondrial translational initiation factor 2
25288 21.68 Acsl1 Rn.6215 Acyl-CoA synthetase long-chain family member 1
25624 21.68 Vamp1 Rn.31977 Vesicle-associated membrane protein 1
252900 21.66 Dgat2 Rn.9523 Diacylglycerol O-acyltransferase homolog 2 (mouse)
Continued on next page
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showed that PLIN2 is upregulated upon loading myotubes
with long-chain FAs and after prolonged consumption of an
HFD or fasting in skeletal muscle of mice. These findings
served as a first indication for a role for PLIN2 in skeletal
muscle lipid metabolism. In subsequent loss-of-function
experiments, we demonstrate that PLIN2 plays an essen-
tial role in skeletal muscle lipid handling. siRNA-mediated
knockdown of PLIN2 prevented intramyocellular TAG
storage. Moreover, palmitate incorporation into DAG and
phospholipids was increased, indicating that PLIN2 is
necessary for FA channeling to TAG in LDs and that in the
absence of PLIN2, part of the FAs are channeled to stor-
age in the form of lipid intermediates other than TAG.
Moreover, LD accumulation was restricted to a few LDs
per myotube upon PLIN2 knockdown, indicating that
PLIN2 is essential for the formation and/or stability of
LDs. Studies toward subcellular localization of LDs in-
dicated that PLIN2 might be involved in budding of LDs
from endoplasmic reticulum (ER) or cell membrane
structures (37,38). Functional involvement of PLIN2 in LD
synthesis has been shown in studies in fibroblasts and
liver (39–41). Our results support a role for PLIN2 in
skeletal muscle LD synthesis, LD stability, and TAG stor-
age.
Next to a lowering in intramyocellular TAG content after
PLIN2 knockdown, we observed less LDs, but the few
existing LDs per cell had a larger size, indicating that the
cell copes with the flux of FAs entering the cells by max-
imizing the volume-to-surface ratio in the few available
LDs. The latter is consistent with the study of Bell et al.
(42) in which PLIN2 knockdown was shown to decrease
LD number while increasing LD size.
Enhancing the partitioning of excess FAs toward TAG
storage is considered to be beneficial in preventing insulin
resistance by limiting the accumulation of lipotoxic lipid
species like ceramides, DAG, and fatty acyl-CoA (28,31).
As our knockdown studies demonstrated that PLIN2 is es-
sential for intramyocellular TAG storage, we investigated
whether PLIN2 overexpression would influence lipid me-
tabolism and lipid-induced insulin resistance. Therefore, we
determined the effects of in vitro PLIN2 overexpression in
C2C12 myotubes and in vivo unilateral, muscle-specific
ectopic PLIN2 expression in rat TA muscle. PLIN2 over-
expression markedly augmented the accumulation of TAG
in LDs, which were both greater in number and larger in
size, consistent with previous studies (40). Short-term in-
corporation of palmitate into both TAG and DAG was in-
creased upon PLIN2 overexpression in myotubes, indicating
increased channeling of FAs toward storage. Increased total
IMCL levels upon prolonged PLIN2 overexpression in
TA muscle (7 days) were not paralleled by increased
intramyocellular DAG levels, indicating that FAs were ef-
ficiently stored as neutral TAG. Moreover, the gene expres-
sion profiles show a shift toward increased gene expression
of genes involved in lipid storage, further supporting the
notion that PLIN2 facilitates intramyocellular TAG storage.
The increase in TAG accumulation was not paralleled
with an increased oxidative capacity. In contrast, the HFD-
induced increase in mitochondrial density was blunted
upon PLIN2 overexpression, and genes involved in FA
TABLE 2
Continued
ID Fold change Gene Unigene Description
171155 21.66 Hadhb Rn.11253 Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase
(trifunctional protein), b subunit
29653 21.65 Gpam Rn.44456 Glycerol-3-phosphate acyltransferase, mitochondrial
25708 21.57 Ucp3 Rn.9902 Uncoupling protein 3 (mitochondrial, proton carrier)
64476 21.56 Mfn2 Rn.8570 Mitofusin 2
192647 21.53 Mfn1 Rn.160939 Mitofusin 1
313510 21.52 Atpaf1 Rn.18579 ATP synthase mitochondrial F1 complex assembly factor 1
353229 21.52 Sgms1 Rn.55975 Sphingomyelin synthase 1
291567 21.52 Ppargc1b Rn.163382 PGC1b
Fold changes in gene expression for a selection of genes are given for PLIN2- versus empty vector–electroporated muscles. Quantitative PCR
was performed for a selection of genes to validate the microarray data (Supplementary Fig. 4).
FIG. 6. Overexpression of PLIN2 in TA muscle of rats on an HFD improves insulin sensitivity of the muscle. Skeletal muscle DAG (A) and ceramide
(B) levels in PLIN2- or empty vector (EV)–electroporated muscle of rats on an HFD. C: 3H-labeled deoxyglucose uptake in control and PLIN2-
electroporated TA muscle of rats on an HFD (n = 11). Error bars represent SEM. *P < 0.05.
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oxidation and mitochondrial function were downregulated.
One could hypothesize that an increased capacity to
efficiently store TAG in muscle would diminish the need
for an increased fat oxidative capacity. Decreased ex-
pression of genes and proteins involved in FA oxidation
has been described previously in conditions of inhibited
lipolysis (43,44). Recent studies show that the regula-
tion of mitochondrial genes by their transcription fac-
tors PPARa and PGC1 requires FAs that are liberated
by lipolysis from LD. Thus, ATGL-deficient mice are
characterized by a marked reduction in mitochondrial
function, which can be rescued by administration of
the peroxisome proliferator–activated receptor agonist
Wy14,643 (45). Likewise, PLIN2 overexpression decreased
gene expression of several PPARa target genes. It could be
hypothesized that PLIN2-facilitated LD storage reduces
lipid turnover, leading to a reduced transcriptional activity
of mitochondrial genes, consistent with the results of our
microarray analysis. In that respect, studies in hepatocytes
and embryonic kidney cells reported an increased lipolysis
after PLIN2 knockdown (41,42,44), indicating that PLIN2
shields the droplet from lipolysis. A proper balance be-
tween IMCL synthesis, lipolysis, and oxidative metabolism
ensures low local intracellular FA levels, thereby preventing
lipotoxicity.
Our study is the first to examine the effects of over-
expression of PLIN2 on insulin sensitivity. PLIN2 loss-of-function
studies in tissues other than muscle showed inconsistent
results on insulin sensitivity (42,46–48). Lowering of PLIN2
activity was demonstrated to improve liver insulin sensi-
tivity in mouse models of PLIN2 inhibition (47,48),
whereas siRNA-mediated knockdown of PLIN2 plus PLIN3
in liver cells impaired insulin sensitivity (42). In our study,
we hypothesized that overexpression of PLIN2, by en-
hancing partitioning of excess fat toward TAG storage,
would improve insulin sensitivity. Whereas, in vitro, PLIN2
knockdown in our hands did not affect insulin sensitivity,
we did indeed find that PLIN2 overexpression completely
rescued palmitate-induced impairments in insulin signal-
ing, in parallel with increased intracellular TAG accumu-
lation. We were able to extend this observation to the in
vivo situation by showing improved insulin sensitivity in
skeletal muscle of PLIN2-electroporated muscle of rats on
an HFD, despite increased IMCL storage. Whereas IMCL
levels were increased, DAG levels were unaffected and,
unexpectedly, ceramide levels were increased upon PLIN2
overexpression. The latter is consistent with the study of
Brown et al. (49), describing that increased ceramide lev-
els associated with lowered lipase activity in liver did not
impair insulin sensitivity (49). This leaves the option open
that the subcellular localization of ceramide (rather than
simply ceramide content) may be a determinant of the lip-
otoxic potential of ceramides.
One limitation of our in vivo study is that our results
only apply to overexpression of PLIN2 in TA muscle,
which is mainly composed of type IIb fibers. Yet, glycolytic
muscles are prone to lipid-induced insulin resistance (50).
Therefore, the observation that overexpression of PLIN2
resulted in excessive lipid storage in the predominantly
glycolytic TA muscle while at the same time improving
insulin-stimulated glucose uptake indicates that PLIN2-
mediated improved partitioning of FAs in LDs is a potent
way to blunt lipid-induced insulin resistance.
We conclude that high levels of PLIN2 are beneficial
for proper storage of TAG in skeletal muscle and thereby
prevent the development of insulin resistance. In that
respect, we recently observed increased PLIN2 levels in
skeletal muscle after training as well as in trained com-
pared with untrained subjects (unpublished data), pro-
viding additional evidence that high PLIN2 levels, even
with high IMCL content, are associated with improved
insulin sensitivity. Likewise, Coen et al. (20) showed
lower PLIN2 gene expression levels in skeletal muscle of
insulin-resistant obese subjects versus BMI-matched in-
sulin-sensitive controls, and both weight loss and phar-
macological insulin-sensitizing strategies (troglitazone or
metformin) resulted in increased PLIN2 protein levels in
skeletal muscle (23).
In summary, using in vitro and in vivo methods, we es-
tablish that PLIN2 is an important facilitator of IMCL
storage. PLIN2 is essential for myocellular TAG storage in
LDs. By improving IMCL storage, PLIN2 protects from
lipotoxicity, resulting in enhanced insulin sensitivity.
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